viewIQ-AI Limited

IQ-AI's portfolio gains commercial and regulatory traction following name change

The firm's subsidiary, Imaging Biometrics, recently appointed a South Korean distributor a few weeks after receiving the first commercial order for its StoneChecker technology

Scans and MRI
The group has also filed a patent for non-toxic MRI technology

IQ-AI Limited (LON:IQAI), formerly known as Flying Brands, has seen commercial and regulatory traction across its portfolio in recent months.

At the end of November, the investment firm’s subsidiary, Imaging Biometrics (IB), said it had appointed a South Korean distributor for its diagnostic imaging products following a number of presentations at hospitals in the country which had generated “significant potential sales interest”.

READ: IQ-AI’s Imaging Biometrics appoints South Korean distributor as it receives regulatory certification

IB develops a number of ready-to-use software applications for the healthcare industry focused around medical imaging for conditions such as brain tumours.

The company has also recently received ISO 13485:2016 certification for its products, an internationally recognised quality standard supporting the design, development, manufacture, and distribution of medical devices that is a regulatory requirement for the industry.

StoneChecker clinches first commercial order

IQ-AI also received the first commercial order for its StoneChecker kidney stone medical imaging software from a “prominent” South Korean hospital.

READ: IQ-AI receives first commercial order for StoneChecker

Given that the country has an estimated 300,000 new cases of kidney stone disease each year, despite a population of only 51mln, South Korea is a key market for IQ-AI.

StoneChecker has already received European CE clearance, while approval from US regulators is expected soon.

Non-toxic MRIs

The group is also working to tackle the relatively new issue of gadolinium toxicity, having filed a patent in October for gadolinium-free magnetic resonance imaging (MRI).

Gadolinium is the name for a group of chemical substances used in MRI scans, however research over the last decade has revealed that the compounds can potentially cause nephrogenic systemic fibrosis (NSF) in a small number of patients, particularly those with compromised kidney functions.

READ: IQ-AI files patent for non-toxic MRI scan technology

IQ-AI reckons it can eliminate the need for gadolinium-based contrast agents in MRI scans, saving healthcare systems money and avoiding the emerging toxicity concerns.

The firm’s invention is based on deep learning techniques – a form of artificial intelligence – using only non-contrast MR images as inputs.

“We believe the potential exists to develop, for the first time, a contrast agent-free imaging technology that should generate output comparable to traditional contrast-based imaging, offering significant savings to global healthcare systems” said David Smith, chief executive of IQ-AI’s operating subsidiaries.

Investors grease the wheels

Shareholders have also been helping to boost momentum at the firm, with the share price rising 18% since early October.

With shares currently trading at around 2.9p, IQ-AI carries a market cap of about £3.6mln.

Quick facts: IQ-AI Limited

Price: 3.325 GBX

Market: LSE
Market Cap: £4.85 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IQ-AI Limited named herein, including the promotion by the Company of IQ-AI Limited in any Content on the Site, the Company receives from said...



Full interview: More from Imaging Biometrics on the AI deal

IQ-AI Limited’s (LON:IQAI) subsidiary, Imaging Biometrics (IB) recently signed a global distribution deal for imaging analysis software designed to detect chronic liver disease (CLD) and CEO Mike Schmainda tells Proactive why that's been so significant. Under the agreement with US firm AI...

on 15/1/20

3 min read